Clinical Gastroenterology and Hepatology-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=579718, encodeId=4f335e971840, content=gas对数据要求大，对创新性要求高，对机制、图片排版这些要求不高。其实并不是很难投。gas里面一些偏临床，数据量不怎么大的，会被要求转投到CGH，总的来说不难，比hep简单多了。因为胃肠病肝病类的几个旗舰刊物gas、gut、hep、jhep都比较牛，下面的杂志又很差，CGH介于中间少有的杂志，捡漏还比较多。所以虽然比那几个简单多了，还是有一定难度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=360, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f8eb1668018, createdName=bigapple001, createdTime=Tue Nov 12 00:00:00 CST 2019, time=2019-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578551, encodeId=04385e8551ba, content=有没有投稿成功的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=304, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576684, encodeId=fa755e66843c, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：妥妥的一区杂志，AGA旗下期刊，gastroenterology 的小弟。一般多数稿件是由gastroenterology 转投过去的，直接投稿命中率不足10%。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/27/31563fd376b0b5aa161e1b65a468d912.jpg, createdBy=237c2098756, createdName=Leopard FD, createdTime=Sat Sep 21 00:00:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562373, encodeId=5e7f5623e389, content=有没有投临床图片报道(image of the month)的朋友，分享下经验。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=787, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/c00242ccb692f0fc07af23dc30809e82/4340b0461b88d04d2cb3cf232a69b8df.jpg, createdBy=ee272000038, createdName=赤脚草医, createdTime=Thu Oct 25 00:00:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551665, encodeId=c50f55166555, content=不是.novel biomarker的发现.收集了百来例样本.分析了一下159****6465(暂无匿称) 2017-12-27 12:20:00 发表: 前瞻性?, beContent=159****6465(暂无匿称) 2017-12-27 12:20:00 发表: 前瞻性?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=945, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Fri Jan 19 00:00:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=550528, encodeId=71835505284b, content=非常好的杂志.谢谢分享, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=927, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/21/9461f3b3c9f14e1d844256cdd08f2cf3.jpg, createdBy=a30f1426910, createdName=swfzhanggui, createdTime=Tue Jan 02 06:20:00 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=550388, encodeId=0069550388e3, content=前瞻性?hongweicheng 2017-10-04 发表:: 投了一篇关于biomarker的.没送审.直接被拒了.样本一百多例.采用的是elisa分析目的分子.结合分析临床指标.分析预后等因素.可能编辑觉得太low了., beContent=hongweicheng 2017-10-04 发表:: 投了一篇关于biomarker的.没送审.直接被拒了.样本一百多例.采用的是elisa分析目的分子.结合分析临床指标.分析预后等因素.可能编辑觉得太low了., objectType=tool_impact_factor, channel=null, level=null, likeNumber=962, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Wed Dec 27 12:20:00 CST 2017, time=2017-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547910, encodeId=886354e910ba, content=投了一篇关于biomarker的.没送审.直接被拒了.样本一百多例.采用的是elisa分析目的分子.结合分析临床指标.分析预后等因素.可能编辑觉得太low了., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=916, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Wed Oct 04 11:23:00 CST 2017, time=2017-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533953, encodeId=067153395351, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：投稿了一篇关于技术改进的回顾性分析，24小时不到就被拒了……（assessed by the Associate Editor and the Board of Editors as the first step in the evaluation of manuscripts ）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1039, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c881636328, createdName=heeda, createdTime=Fri Mar 10 10:01:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=531605, encodeId=587c531605b0, content=请问各位前辈：在投稿过程中我一步一步按照顺序填写文章的信息，但作者那栏始终没显示表示该项已填写成功的对号图案，别的栏填完之后都有对号；一路点击next，到了上传files这一步之后再点击next，就到了显示文章现在的状态的页面，始终显示incomplete，不明白为啥啊啊啊啊啊，不明白问题出在了哪儿，求前辈们指导。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1025, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64c32006937, createdName=Dr.Carrisa, createdTime=Sun Jan 08 15:54:00 CST 2017, time=2017-01-08, status=1, ipAttribution=)]

2019-11-12 bigapple001

gas对数据要求大，对创新性要求高，对机制、图片排版这些要求不高。其实并不是很难投。gas里面一些偏临床，数据量不怎么大的，会被要求转投到CGH，总的来说不难，比hep简单多了。因为胃肠病肝病类的几个旗舰刊物gas、gut、hep、jhep都比较牛，下面的杂志又很差，CGH介于中间少有的杂志，捡漏还比较多。所以虽然比那几个简单多了，还是有一定难度。

360 0

[GetPortalCommentsPageByObjectIdResponse(id=579718, encodeId=4f335e971840, content=gas对数据要求大，对创新性要求高，对机制、图片排版这些要求不高。其实并不是很难投。gas里面一些偏临床，数据量不怎么大的，会被要求转投到CGH，总的来说不难，比hep简单多了。因为胃肠病肝病类的几个旗舰刊物gas、gut、hep、jhep都比较牛，下面的杂志又很差，CGH介于中间少有的杂志，捡漏还比较多。所以虽然比那几个简单多了，还是有一定难度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=360, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f8eb1668018, createdName=bigapple001, createdTime=Tue Nov 12 00:00:00 CST 2019, time=2019-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578551, encodeId=04385e8551ba, content=有没有投稿成功的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=304, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576684, encodeId=fa755e66843c, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：妥妥的一区杂志，AGA旗下期刊，gastroenterology 的小弟。一般多数稿件是由gastroenterology 转投过去的，直接投稿命中率不足10%。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/27/31563fd376b0b5aa161e1b65a468d912.jpg, createdBy=237c2098756, createdName=Leopard FD, createdTime=Sat Sep 21 00:00:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562373, encodeId=5e7f5623e389, content=有没有投临床图片报道(image of the month)的朋友，分享下经验。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=787, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/c00242ccb692f0fc07af23dc30809e82/4340b0461b88d04d2cb3cf232a69b8df.jpg, createdBy=ee272000038, createdName=赤脚草医, createdTime=Thu Oct 25 00:00:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551665, encodeId=c50f55166555, content=不是.novel biomarker的发现.收集了百来例样本.分析了一下159****6465(暂无匿称) 2017-12-27 12:20:00 发表: 前瞻性?, beContent=159****6465(暂无匿称) 2017-12-27 12:20:00 发表: 前瞻性?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=945, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Fri Jan 19 00:00:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=550528, encodeId=71835505284b, content=非常好的杂志.谢谢分享, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=927, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/21/9461f3b3c9f14e1d844256cdd08f2cf3.jpg, createdBy=a30f1426910, createdName=swfzhanggui, createdTime=Tue Jan 02 06:20:00 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=550388, encodeId=0069550388e3, content=前瞻性?hongweicheng 2017-10-04 发表:: 投了一篇关于biomarker的.没送审.直接被拒了.样本一百多例.采用的是elisa分析目的分子.结合分析临床指标.分析预后等因素.可能编辑觉得太low了., beContent=hongweicheng 2017-10-04 发表:: 投了一篇关于biomarker的.没送审.直接被拒了.样本一百多例.采用的是elisa分析目的分子.结合分析临床指标.分析预后等因素.可能编辑觉得太low了., objectType=tool_impact_factor, channel=null, level=null, likeNumber=962, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Wed Dec 27 12:20:00 CST 2017, time=2017-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547910, encodeId=886354e910ba, content=投了一篇关于biomarker的.没送审.直接被拒了.样本一百多例.采用的是elisa分析目的分子.结合分析临床指标.分析预后等因素.可能编辑觉得太low了., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=916, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Wed Oct 04 11:23:00 CST 2017, time=2017-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533953, encodeId=067153395351, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：投稿了一篇关于技术改进的回顾性分析，24小时不到就被拒了……（assessed by the Associate Editor and the Board of Editors as the first step in the evaluation of manuscripts ）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1039, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c881636328, createdName=heeda, createdTime=Fri Mar 10 10:01:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=531605, encodeId=587c531605b0, content=请问各位前辈：在投稿过程中我一步一步按照顺序填写文章的信息，但作者那栏始终没显示表示该项已填写成功的对号图案，别的栏填完之后都有对号；一路点击next，到了上传files这一步之后再点击next，就到了显示文章现在的状态的页面，始终显示incomplete，不明白为啥啊啊啊啊啊，不明白问题出在了哪儿，求前辈们指导。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1025, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64c32006937, createdName=Dr.Carrisa, createdTime=Sun Jan 08 15:54:00 CST 2017, time=2017-01-08, status=1, ipAttribution=)]

2019-10-25 147612bem32暂无昵称

有没有投稿成功的

304 0

[GetPortalCommentsPageByObjectIdResponse(id=579718, encodeId=4f335e971840, content=gas对数据要求大，对创新性要求高，对机制、图片排版这些要求不高。其实并不是很难投。gas里面一些偏临床，数据量不怎么大的，会被要求转投到CGH，总的来说不难，比hep简单多了。因为胃肠病肝病类的几个旗舰刊物gas、gut、hep、jhep都比较牛，下面的杂志又很差，CGH介于中间少有的杂志，捡漏还比较多。所以虽然比那几个简单多了，还是有一定难度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=360, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f8eb1668018, createdName=bigapple001, createdTime=Tue Nov 12 00:00:00 CST 2019, time=2019-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578551, encodeId=04385e8551ba, content=有没有投稿成功的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=304, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576684, encodeId=fa755e66843c, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：妥妥的一区杂志，AGA旗下期刊，gastroenterology 的小弟。一般多数稿件是由gastroenterology 转投过去的，直接投稿命中率不足10%。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/27/31563fd376b0b5aa161e1b65a468d912.jpg, createdBy=237c2098756, createdName=Leopard FD, createdTime=Sat Sep 21 00:00:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562373, encodeId=5e7f5623e389, content=有没有投临床图片报道(image of the month)的朋友，分享下经验。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=787, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/c00242ccb692f0fc07af23dc30809e82/4340b0461b88d04d2cb3cf232a69b8df.jpg, createdBy=ee272000038, createdName=赤脚草医, createdTime=Thu Oct 25 00:00:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551665, encodeId=c50f55166555, content=不是.novel biomarker的发现.收集了百来例样本.分析了一下159****6465(暂无匿称) 2017-12-27 12:20:00 发表: 前瞻性?, beContent=159****6465(暂无匿称) 2017-12-27 12:20:00 发表: 前瞻性?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=945, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Fri Jan 19 00:00:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=550528, encodeId=71835505284b, content=非常好的杂志.谢谢分享, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=927, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/21/9461f3b3c9f14e1d844256cdd08f2cf3.jpg, createdBy=a30f1426910, createdName=swfzhanggui, createdTime=Tue Jan 02 06:20:00 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=550388, encodeId=0069550388e3, content=前瞻性?hongweicheng 2017-10-04 发表:: 投了一篇关于biomarker的.没送审.直接被拒了.样本一百多例.采用的是elisa分析目的分子.结合分析临床指标.分析预后等因素.可能编辑觉得太low了., beContent=hongweicheng 2017-10-04 发表:: 投了一篇关于biomarker的.没送审.直接被拒了.样本一百多例.采用的是elisa分析目的分子.结合分析临床指标.分析预后等因素.可能编辑觉得太low了., objectType=tool_impact_factor, channel=null, level=null, likeNumber=962, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Wed Dec 27 12:20:00 CST 2017, time=2017-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547910, encodeId=886354e910ba, content=投了一篇关于biomarker的.没送审.直接被拒了.样本一百多例.采用的是elisa分析目的分子.结合分析临床指标.分析预后等因素.可能编辑觉得太low了., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=916, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Wed Oct 04 11:23:00 CST 2017, time=2017-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533953, encodeId=067153395351, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：投稿了一篇关于技术改进的回顾性分析，24小时不到就被拒了……（assessed by the Associate Editor and the Board of Editors as the first step in the evaluation of manuscripts ）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1039, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c881636328, createdName=heeda, createdTime=Fri Mar 10 10:01:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=531605, encodeId=587c531605b0, content=请问各位前辈：在投稿过程中我一步一步按照顺序填写文章的信息，但作者那栏始终没显示表示该项已填写成功的对号图案，别的栏填完之后都有对号；一路点击next，到了上传files这一步之后再点击next，就到了显示文章现在的状态的页面，始终显示incomplete，不明白为啥啊啊啊啊啊，不明白问题出在了哪儿，求前辈们指导。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1025, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64c32006937, createdName=Dr.Carrisa, createdTime=Sun Jan 08 15:54:00 CST 2017, time=2017-01-08, status=1, ipAttribution=)]

2019-09-21 Leopard FD

审稿速度:2.0 | 投稿命中率:25.0
经验分享：妥妥的一区杂志，AGA旗下期刊，gastroenterology 的小弟。一般多数稿件是由gastroenterology 转投过去的，直接投稿命中率不足10%。

195 0

[GetPortalCommentsPageByObjectIdResponse(id=579718, encodeId=4f335e971840, content=gas对数据要求大，对创新性要求高，对机制、图片排版这些要求不高。其实并不是很难投。gas里面一些偏临床，数据量不怎么大的，会被要求转投到CGH，总的来说不难，比hep简单多了。因为胃肠病肝病类的几个旗舰刊物gas、gut、hep、jhep都比较牛，下面的杂志又很差，CGH介于中间少有的杂志，捡漏还比较多。所以虽然比那几个简单多了，还是有一定难度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=360, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f8eb1668018, createdName=bigapple001, createdTime=Tue Nov 12 00:00:00 CST 2019, time=2019-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578551, encodeId=04385e8551ba, content=有没有投稿成功的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=304, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576684, encodeId=fa755e66843c, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：妥妥的一区杂志，AGA旗下期刊，gastroenterology 的小弟。一般多数稿件是由gastroenterology 转投过去的，直接投稿命中率不足10%。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/27/31563fd376b0b5aa161e1b65a468d912.jpg, createdBy=237c2098756, createdName=Leopard FD, createdTime=Sat Sep 21 00:00:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562373, encodeId=5e7f5623e389, content=有没有投临床图片报道(image of the month)的朋友，分享下经验。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=787, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/c00242ccb692f0fc07af23dc30809e82/4340b0461b88d04d2cb3cf232a69b8df.jpg, createdBy=ee272000038, createdName=赤脚草医, createdTime=Thu Oct 25 00:00:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551665, encodeId=c50f55166555, content=不是.novel biomarker的发现.收集了百来例样本.分析了一下159****6465(暂无匿称) 2017-12-27 12:20:00 发表: 前瞻性?, beContent=159****6465(暂无匿称) 2017-12-27 12:20:00 发表: 前瞻性?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=945, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Fri Jan 19 00:00:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=550528, encodeId=71835505284b, content=非常好的杂志.谢谢分享, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=927, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/21/9461f3b3c9f14e1d844256cdd08f2cf3.jpg, createdBy=a30f1426910, createdName=swfzhanggui, createdTime=Tue Jan 02 06:20:00 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=550388, encodeId=0069550388e3, content=前瞻性?hongweicheng 2017-10-04 发表:: 投了一篇关于biomarker的.没送审.直接被拒了.样本一百多例.采用的是elisa分析目的分子.结合分析临床指标.分析预后等因素.可能编辑觉得太low了., beContent=hongweicheng 2017-10-04 发表:: 投了一篇关于biomarker的.没送审.直接被拒了.样本一百多例.采用的是elisa分析目的分子.结合分析临床指标.分析预后等因素.可能编辑觉得太low了., objectType=tool_impact_factor, channel=null, level=null, likeNumber=962, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Wed Dec 27 12:20:00 CST 2017, time=2017-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547910, encodeId=886354e910ba, content=投了一篇关于biomarker的.没送审.直接被拒了.样本一百多例.采用的是elisa分析目的分子.结合分析临床指标.分析预后等因素.可能编辑觉得太low了., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=916, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Wed Oct 04 11:23:00 CST 2017, time=2017-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533953, encodeId=067153395351, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：投稿了一篇关于技术改进的回顾性分析，24小时不到就被拒了……（assessed by the Associate Editor and the Board of Editors as the first step in the evaluation of manuscripts ）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1039, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c881636328, createdName=heeda, createdTime=Fri Mar 10 10:01:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=531605, encodeId=587c531605b0, content=请问各位前辈：在投稿过程中我一步一步按照顺序填写文章的信息，但作者那栏始终没显示表示该项已填写成功的对号图案，别的栏填完之后都有对号；一路点击next，到了上传files这一步之后再点击next，就到了显示文章现在的状态的页面，始终显示incomplete，不明白为啥啊啊啊啊啊，不明白问题出在了哪儿，求前辈们指导。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1025, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64c32006937, createdName=Dr.Carrisa, createdTime=Sun Jan 08 15:54:00 CST 2017, time=2017-01-08, status=1, ipAttribution=)]

2018-10-25 赤脚草医

有没有投临床图片报道(image of the month)的朋友，分享下经验。

787 0

[GetPortalCommentsPageByObjectIdResponse(id=579718, encodeId=4f335e971840, content=gas对数据要求大，对创新性要求高，对机制、图片排版这些要求不高。其实并不是很难投。gas里面一些偏临床，数据量不怎么大的，会被要求转投到CGH，总的来说不难，比hep简单多了。因为胃肠病肝病类的几个旗舰刊物gas、gut、hep、jhep都比较牛，下面的杂志又很差，CGH介于中间少有的杂志，捡漏还比较多。所以虽然比那几个简单多了，还是有一定难度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=360, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f8eb1668018, createdName=bigapple001, createdTime=Tue Nov 12 00:00:00 CST 2019, time=2019-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578551, encodeId=04385e8551ba, content=有没有投稿成功的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=304, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576684, encodeId=fa755e66843c, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：妥妥的一区杂志，AGA旗下期刊，gastroenterology 的小弟。一般多数稿件是由gastroenterology 转投过去的，直接投稿命中率不足10%。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/27/31563fd376b0b5aa161e1b65a468d912.jpg, createdBy=237c2098756, createdName=Leopard FD, createdTime=Sat Sep 21 00:00:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562373, encodeId=5e7f5623e389, content=有没有投临床图片报道(image of the month)的朋友，分享下经验。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=787, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/c00242ccb692f0fc07af23dc30809e82/4340b0461b88d04d2cb3cf232a69b8df.jpg, createdBy=ee272000038, createdName=赤脚草医, createdTime=Thu Oct 25 00:00:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551665, encodeId=c50f55166555, content=不是.novel biomarker的发现.收集了百来例样本.分析了一下159****6465(暂无匿称) 2017-12-27 12:20:00 发表: 前瞻性?, beContent=159****6465(暂无匿称) 2017-12-27 12:20:00 发表: 前瞻性?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=945, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Fri Jan 19 00:00:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=550528, encodeId=71835505284b, content=非常好的杂志.谢谢分享, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=927, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/21/9461f3b3c9f14e1d844256cdd08f2cf3.jpg, createdBy=a30f1426910, createdName=swfzhanggui, createdTime=Tue Jan 02 06:20:00 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=550388, encodeId=0069550388e3, content=前瞻性?hongweicheng 2017-10-04 发表:: 投了一篇关于biomarker的.没送审.直接被拒了.样本一百多例.采用的是elisa分析目的分子.结合分析临床指标.分析预后等因素.可能编辑觉得太low了., beContent=hongweicheng 2017-10-04 发表:: 投了一篇关于biomarker的.没送审.直接被拒了.样本一百多例.采用的是elisa分析目的分子.结合分析临床指标.分析预后等因素.可能编辑觉得太low了., objectType=tool_impact_factor, channel=null, level=null, likeNumber=962, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Wed Dec 27 12:20:00 CST 2017, time=2017-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547910, encodeId=886354e910ba, content=投了一篇关于biomarker的.没送审.直接被拒了.样本一百多例.采用的是elisa分析目的分子.结合分析临床指标.分析预后等因素.可能编辑觉得太low了., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=916, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Wed Oct 04 11:23:00 CST 2017, time=2017-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533953, encodeId=067153395351, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：投稿了一篇关于技术改进的回顾性分析，24小时不到就被拒了……（assessed by the Associate Editor and the Board of Editors as the first step in the evaluation of manuscripts ）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1039, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c881636328, createdName=heeda, createdTime=Fri Mar 10 10:01:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=531605, encodeId=587c531605b0, content=请问各位前辈：在投稿过程中我一步一步按照顺序填写文章的信息，但作者那栏始终没显示表示该项已填写成功的对号图案，别的栏填完之后都有对号；一路点击next，到了上传files这一步之后再点击next，就到了显示文章现在的状态的页面，始终显示incomplete，不明白为啥啊啊啊啊啊，不明白问题出在了哪儿，求前辈们指导。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1025, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64c32006937, createdName=Dr.Carrisa, createdTime=Sun Jan 08 15:54:00 CST 2017, time=2017-01-08, status=1, ipAttribution=)]

2018-01-19 hongweicheng

不是.novel biomarker的发现.收集了百来例样本.分析了一下159****6465(暂无匿称) 2017-12-27 12:20:00 发表:
前瞻性?

159****6465(暂无匿称) 2017-12-27 12:20:00 发表: 前瞻性?

945 0

[GetPortalCommentsPageByObjectIdResponse(id=579718, encodeId=4f335e971840, content=gas对数据要求大，对创新性要求高，对机制、图片排版这些要求不高。其实并不是很难投。gas里面一些偏临床，数据量不怎么大的，会被要求转投到CGH，总的来说不难，比hep简单多了。因为胃肠病肝病类的几个旗舰刊物gas、gut、hep、jhep都比较牛，下面的杂志又很差，CGH介于中间少有的杂志，捡漏还比较多。所以虽然比那几个简单多了，还是有一定难度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=360, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f8eb1668018, createdName=bigapple001, createdTime=Tue Nov 12 00:00:00 CST 2019, time=2019-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578551, encodeId=04385e8551ba, content=有没有投稿成功的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=304, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576684, encodeId=fa755e66843c, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：妥妥的一区杂志，AGA旗下期刊，gastroenterology 的小弟。一般多数稿件是由gastroenterology 转投过去的，直接投稿命中率不足10%。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/27/31563fd376b0b5aa161e1b65a468d912.jpg, createdBy=237c2098756, createdName=Leopard FD, createdTime=Sat Sep 21 00:00:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562373, encodeId=5e7f5623e389, content=有没有投临床图片报道(image of the month)的朋友，分享下经验。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=787, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/c00242ccb692f0fc07af23dc30809e82/4340b0461b88d04d2cb3cf232a69b8df.jpg, createdBy=ee272000038, createdName=赤脚草医, createdTime=Thu Oct 25 00:00:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551665, encodeId=c50f55166555, content=不是.novel biomarker的发现.收集了百来例样本.分析了一下159****6465(暂无匿称) 2017-12-27 12:20:00 发表: 前瞻性?, beContent=159****6465(暂无匿称) 2017-12-27 12:20:00 发表: 前瞻性?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=945, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Fri Jan 19 00:00:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=550528, encodeId=71835505284b, content=非常好的杂志.谢谢分享, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=927, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/21/9461f3b3c9f14e1d844256cdd08f2cf3.jpg, createdBy=a30f1426910, createdName=swfzhanggui, createdTime=Tue Jan 02 06:20:00 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=550388, encodeId=0069550388e3, content=前瞻性?hongweicheng 2017-10-04 发表:: 投了一篇关于biomarker的.没送审.直接被拒了.样本一百多例.采用的是elisa分析目的分子.结合分析临床指标.分析预后等因素.可能编辑觉得太low了., beContent=hongweicheng 2017-10-04 发表:: 投了一篇关于biomarker的.没送审.直接被拒了.样本一百多例.采用的是elisa分析目的分子.结合分析临床指标.分析预后等因素.可能编辑觉得太low了., objectType=tool_impact_factor, channel=null, level=null, likeNumber=962, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Wed Dec 27 12:20:00 CST 2017, time=2017-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547910, encodeId=886354e910ba, content=投了一篇关于biomarker的.没送审.直接被拒了.样本一百多例.采用的是elisa分析目的分子.结合分析临床指标.分析预后等因素.可能编辑觉得太low了., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=916, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Wed Oct 04 11:23:00 CST 2017, time=2017-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533953, encodeId=067153395351, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：投稿了一篇关于技术改进的回顾性分析，24小时不到就被拒了……（assessed by the Associate Editor and the Board of Editors as the first step in the evaluation of manuscripts ）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1039, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c881636328, createdName=heeda, createdTime=Fri Mar 10 10:01:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=531605, encodeId=587c531605b0, content=请问各位前辈：在投稿过程中我一步一步按照顺序填写文章的信息，但作者那栏始终没显示表示该项已填写成功的对号图案，别的栏填完之后都有对号；一路点击next，到了上传files这一步之后再点击next，就到了显示文章现在的状态的页面，始终显示incomplete，不明白为啥啊啊啊啊啊，不明白问题出在了哪儿，求前辈们指导。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1025, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64c32006937, createdName=Dr.Carrisa, createdTime=Sun Jan 08 15:54:00 CST 2017, time=2017-01-08, status=1, ipAttribution=)]

2018-01-02 swfzhanggui

非常好的杂志.谢谢分享

927 0

[GetPortalCommentsPageByObjectIdResponse(id=579718, encodeId=4f335e971840, content=gas对数据要求大，对创新性要求高，对机制、图片排版这些要求不高。其实并不是很难投。gas里面一些偏临床，数据量不怎么大的，会被要求转投到CGH，总的来说不难，比hep简单多了。因为胃肠病肝病类的几个旗舰刊物gas、gut、hep、jhep都比较牛，下面的杂志又很差，CGH介于中间少有的杂志，捡漏还比较多。所以虽然比那几个简单多了，还是有一定难度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=360, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f8eb1668018, createdName=bigapple001, createdTime=Tue Nov 12 00:00:00 CST 2019, time=2019-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578551, encodeId=04385e8551ba, content=有没有投稿成功的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=304, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576684, encodeId=fa755e66843c, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：妥妥的一区杂志，AGA旗下期刊，gastroenterology 的小弟。一般多数稿件是由gastroenterology 转投过去的，直接投稿命中率不足10%。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/27/31563fd376b0b5aa161e1b65a468d912.jpg, createdBy=237c2098756, createdName=Leopard FD, createdTime=Sat Sep 21 00:00:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562373, encodeId=5e7f5623e389, content=有没有投临床图片报道(image of the month)的朋友，分享下经验。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=787, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/c00242ccb692f0fc07af23dc30809e82/4340b0461b88d04d2cb3cf232a69b8df.jpg, createdBy=ee272000038, createdName=赤脚草医, createdTime=Thu Oct 25 00:00:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551665, encodeId=c50f55166555, content=不是.novel biomarker的发现.收集了百来例样本.分析了一下159****6465(暂无匿称) 2017-12-27 12:20:00 发表: 前瞻性?, beContent=159****6465(暂无匿称) 2017-12-27 12:20:00 发表: 前瞻性?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=945, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Fri Jan 19 00:00:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=550528, encodeId=71835505284b, content=非常好的杂志.谢谢分享, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=927, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/21/9461f3b3c9f14e1d844256cdd08f2cf3.jpg, createdBy=a30f1426910, createdName=swfzhanggui, createdTime=Tue Jan 02 06:20:00 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=550388, encodeId=0069550388e3, content=前瞻性?hongweicheng 2017-10-04 发表:: 投了一篇关于biomarker的.没送审.直接被拒了.样本一百多例.采用的是elisa分析目的分子.结合分析临床指标.分析预后等因素.可能编辑觉得太low了., beContent=hongweicheng 2017-10-04 发表:: 投了一篇关于biomarker的.没送审.直接被拒了.样本一百多例.采用的是elisa分析目的分子.结合分析临床指标.分析预后等因素.可能编辑觉得太low了., objectType=tool_impact_factor, channel=null, level=null, likeNumber=962, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Wed Dec 27 12:20:00 CST 2017, time=2017-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547910, encodeId=886354e910ba, content=投了一篇关于biomarker的.没送审.直接被拒了.样本一百多例.采用的是elisa分析目的分子.结合分析临床指标.分析预后等因素.可能编辑觉得太low了., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=916, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Wed Oct 04 11:23:00 CST 2017, time=2017-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533953, encodeId=067153395351, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：投稿了一篇关于技术改进的回顾性分析，24小时不到就被拒了……（assessed by the Associate Editor and the Board of Editors as the first step in the evaluation of manuscripts ）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1039, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c881636328, createdName=heeda, createdTime=Fri Mar 10 10:01:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=531605, encodeId=587c531605b0, content=请问各位前辈：在投稿过程中我一步一步按照顺序填写文章的信息，但作者那栏始终没显示表示该项已填写成功的对号图案，别的栏填完之后都有对号；一路点击next，到了上传files这一步之后再点击next，就到了显示文章现在的状态的页面，始终显示incomplete，不明白为啥啊啊啊啊啊，不明白问题出在了哪儿，求前辈们指导。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1025, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64c32006937, createdName=Dr.Carrisa, createdTime=Sun Jan 08 15:54:00 CST 2017, time=2017-01-08, status=1, ipAttribution=)]

2017-12-27 1e2321c7m65(暂无匿称)

前瞻性?hongweicheng 2017-10-04 发表::
投了一篇关于biomarker的.没送审.直接被拒了.样本一百多例.采用的是elisa分析目的分子.结合分析临床指标.分析预后等因素.可能编辑觉得太low了.

hongweicheng 2017-10-04 发表:: 投了一篇关于biomarker的.没送审.直接被拒了.样本一百多例.采用的是elisa分析目的分子.结合分析临床指标.分析预后等因素.可能编辑觉得太low了.

962 0

[GetPortalCommentsPageByObjectIdResponse(id=579718, encodeId=4f335e971840, content=gas对数据要求大，对创新性要求高，对机制、图片排版这些要求不高。其实并不是很难投。gas里面一些偏临床，数据量不怎么大的，会被要求转投到CGH，总的来说不难，比hep简单多了。因为胃肠病肝病类的几个旗舰刊物gas、gut、hep、jhep都比较牛，下面的杂志又很差，CGH介于中间少有的杂志，捡漏还比较多。所以虽然比那几个简单多了，还是有一定难度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=360, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f8eb1668018, createdName=bigapple001, createdTime=Tue Nov 12 00:00:00 CST 2019, time=2019-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578551, encodeId=04385e8551ba, content=有没有投稿成功的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=304, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576684, encodeId=fa755e66843c, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：妥妥的一区杂志，AGA旗下期刊，gastroenterology 的小弟。一般多数稿件是由gastroenterology 转投过去的，直接投稿命中率不足10%。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/27/31563fd376b0b5aa161e1b65a468d912.jpg, createdBy=237c2098756, createdName=Leopard FD, createdTime=Sat Sep 21 00:00:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562373, encodeId=5e7f5623e389, content=有没有投临床图片报道(image of the month)的朋友，分享下经验。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=787, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/c00242ccb692f0fc07af23dc30809e82/4340b0461b88d04d2cb3cf232a69b8df.jpg, createdBy=ee272000038, createdName=赤脚草医, createdTime=Thu Oct 25 00:00:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551665, encodeId=c50f55166555, content=不是.novel biomarker的发现.收集了百来例样本.分析了一下159****6465(暂无匿称) 2017-12-27 12:20:00 发表: 前瞻性?, beContent=159****6465(暂无匿称) 2017-12-27 12:20:00 发表: 前瞻性?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=945, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Fri Jan 19 00:00:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=550528, encodeId=71835505284b, content=非常好的杂志.谢谢分享, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=927, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/21/9461f3b3c9f14e1d844256cdd08f2cf3.jpg, createdBy=a30f1426910, createdName=swfzhanggui, createdTime=Tue Jan 02 06:20:00 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=550388, encodeId=0069550388e3, content=前瞻性?hongweicheng 2017-10-04 发表:: 投了一篇关于biomarker的.没送审.直接被拒了.样本一百多例.采用的是elisa分析目的分子.结合分析临床指标.分析预后等因素.可能编辑觉得太low了., beContent=hongweicheng 2017-10-04 发表:: 投了一篇关于biomarker的.没送审.直接被拒了.样本一百多例.采用的是elisa分析目的分子.结合分析临床指标.分析预后等因素.可能编辑觉得太low了., objectType=tool_impact_factor, channel=null, level=null, likeNumber=962, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Wed Dec 27 12:20:00 CST 2017, time=2017-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547910, encodeId=886354e910ba, content=投了一篇关于biomarker的.没送审.直接被拒了.样本一百多例.采用的是elisa分析目的分子.结合分析临床指标.分析预后等因素.可能编辑觉得太low了., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=916, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Wed Oct 04 11:23:00 CST 2017, time=2017-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533953, encodeId=067153395351, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：投稿了一篇关于技术改进的回顾性分析，24小时不到就被拒了……（assessed by the Associate Editor and the Board of Editors as the first step in the evaluation of manuscripts ）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1039, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c881636328, createdName=heeda, createdTime=Fri Mar 10 10:01:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=531605, encodeId=587c531605b0, content=请问各位前辈：在投稿过程中我一步一步按照顺序填写文章的信息，但作者那栏始终没显示表示该项已填写成功的对号图案，别的栏填完之后都有对号；一路点击next，到了上传files这一步之后再点击next，就到了显示文章现在的状态的页面，始终显示incomplete，不明白为啥啊啊啊啊啊，不明白问题出在了哪儿，求前辈们指导。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1025, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64c32006937, createdName=Dr.Carrisa, createdTime=Sun Jan 08 15:54:00 CST 2017, time=2017-01-08, status=1, ipAttribution=)]

2017-10-04 hongweicheng

投了一篇关于biomarker的.没送审.直接被拒了.样本一百多例.采用的是elisa分析目的分子.结合分析临床指标.分析预后等因素.可能编辑觉得太low了.

916 0

[GetPortalCommentsPageByObjectIdResponse(id=579718, encodeId=4f335e971840, content=gas对数据要求大，对创新性要求高，对机制、图片排版这些要求不高。其实并不是很难投。gas里面一些偏临床，数据量不怎么大的，会被要求转投到CGH，总的来说不难，比hep简单多了。因为胃肠病肝病类的几个旗舰刊物gas、gut、hep、jhep都比较牛，下面的杂志又很差，CGH介于中间少有的杂志，捡漏还比较多。所以虽然比那几个简单多了，还是有一定难度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=360, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f8eb1668018, createdName=bigapple001, createdTime=Tue Nov 12 00:00:00 CST 2019, time=2019-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578551, encodeId=04385e8551ba, content=有没有投稿成功的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=304, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576684, encodeId=fa755e66843c, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：妥妥的一区杂志，AGA旗下期刊，gastroenterology 的小弟。一般多数稿件是由gastroenterology 转投过去的，直接投稿命中率不足10%。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/27/31563fd376b0b5aa161e1b65a468d912.jpg, createdBy=237c2098756, createdName=Leopard FD, createdTime=Sat Sep 21 00:00:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562373, encodeId=5e7f5623e389, content=有没有投临床图片报道(image of the month)的朋友，分享下经验。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=787, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/c00242ccb692f0fc07af23dc30809e82/4340b0461b88d04d2cb3cf232a69b8df.jpg, createdBy=ee272000038, createdName=赤脚草医, createdTime=Thu Oct 25 00:00:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551665, encodeId=c50f55166555, content=不是.novel biomarker的发现.收集了百来例样本.分析了一下159****6465(暂无匿称) 2017-12-27 12:20:00 发表: 前瞻性?, beContent=159****6465(暂无匿称) 2017-12-27 12:20:00 发表: 前瞻性?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=945, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Fri Jan 19 00:00:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=550528, encodeId=71835505284b, content=非常好的杂志.谢谢分享, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=927, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/21/9461f3b3c9f14e1d844256cdd08f2cf3.jpg, createdBy=a30f1426910, createdName=swfzhanggui, createdTime=Tue Jan 02 06:20:00 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=550388, encodeId=0069550388e3, content=前瞻性?hongweicheng 2017-10-04 发表:: 投了一篇关于biomarker的.没送审.直接被拒了.样本一百多例.采用的是elisa分析目的分子.结合分析临床指标.分析预后等因素.可能编辑觉得太low了., beContent=hongweicheng 2017-10-04 发表:: 投了一篇关于biomarker的.没送审.直接被拒了.样本一百多例.采用的是elisa分析目的分子.结合分析临床指标.分析预后等因素.可能编辑觉得太low了., objectType=tool_impact_factor, channel=null, level=null, likeNumber=962, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Wed Dec 27 12:20:00 CST 2017, time=2017-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547910, encodeId=886354e910ba, content=投了一篇关于biomarker的.没送审.直接被拒了.样本一百多例.采用的是elisa分析目的分子.结合分析临床指标.分析预后等因素.可能编辑觉得太low了., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=916, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Wed Oct 04 11:23:00 CST 2017, time=2017-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533953, encodeId=067153395351, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：投稿了一篇关于技术改进的回顾性分析，24小时不到就被拒了……（assessed by the Associate Editor and the Board of Editors as the first step in the evaluation of manuscripts ）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1039, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c881636328, createdName=heeda, createdTime=Fri Mar 10 10:01:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=531605, encodeId=587c531605b0, content=请问各位前辈：在投稿过程中我一步一步按照顺序填写文章的信息，但作者那栏始终没显示表示该项已填写成功的对号图案，别的栏填完之后都有对号；一路点击next，到了上传files这一步之后再点击next，就到了显示文章现在的状态的页面，始终显示incomplete，不明白为啥啊啊啊啊啊，不明白问题出在了哪儿，求前辈们指导。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1025, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64c32006937, createdName=Dr.Carrisa, createdTime=Sun Jan 08 15:54:00 CST 2017, time=2017-01-08, status=1, ipAttribution=)]

2017-03-10 heeda

审稿速度:1.0 | 投稿命中率:5.0
经验分享：投稿了一篇关于技术改进的回顾性分析，24小时不到就被拒了……（assessed by the Associate Editor and the Board of Editors as the first step in the evaluation of manuscripts ）

1039 0

[GetPortalCommentsPageByObjectIdResponse(id=579718, encodeId=4f335e971840, content=gas对数据要求大，对创新性要求高，对机制、图片排版这些要求不高。其实并不是很难投。gas里面一些偏临床，数据量不怎么大的，会被要求转投到CGH，总的来说不难，比hep简单多了。因为胃肠病肝病类的几个旗舰刊物gas、gut、hep、jhep都比较牛，下面的杂志又很差，CGH介于中间少有的杂志，捡漏还比较多。所以虽然比那几个简单多了，还是有一定难度。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=360, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f8eb1668018, createdName=bigapple001, createdTime=Tue Nov 12 00:00:00 CST 2019, time=2019-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=578551, encodeId=04385e8551ba, content=有没有投稿成功的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=304, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 00:00:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=576684, encodeId=fa755e66843c, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：妥妥的一区杂志，AGA旗下期刊，gastroenterology 的小弟。一般多数稿件是由gastroenterology 转投过去的，直接投稿命中率不足10%。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/27/31563fd376b0b5aa161e1b65a468d912.jpg, createdBy=237c2098756, createdName=Leopard FD, createdTime=Sat Sep 21 00:00:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=562373, encodeId=5e7f5623e389, content=有没有投临床图片报道(image of the month)的朋友，分享下经验。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=787, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/c00242ccb692f0fc07af23dc30809e82/4340b0461b88d04d2cb3cf232a69b8df.jpg, createdBy=ee272000038, createdName=赤脚草医, createdTime=Thu Oct 25 00:00:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551665, encodeId=c50f55166555, content=不是.novel biomarker的发现.收集了百来例样本.分析了一下159****6465(暂无匿称) 2017-12-27 12:20:00 发表: 前瞻性?, beContent=159****6465(暂无匿称) 2017-12-27 12:20:00 发表: 前瞻性?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=945, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Fri Jan 19 00:00:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=550528, encodeId=71835505284b, content=非常好的杂志.谢谢分享, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=927, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/21/9461f3b3c9f14e1d844256cdd08f2cf3.jpg, createdBy=a30f1426910, createdName=swfzhanggui, createdTime=Tue Jan 02 06:20:00 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=550388, encodeId=0069550388e3, content=前瞻性?hongweicheng 2017-10-04 发表:: 投了一篇关于biomarker的.没送审.直接被拒了.样本一百多例.采用的是elisa分析目的分子.结合分析临床指标.分析预后等因素.可能编辑觉得太low了., beContent=hongweicheng 2017-10-04 发表:: 投了一篇关于biomarker的.没送审.直接被拒了.样本一百多例.采用的是elisa分析目的分子.结合分析临床指标.分析预后等因素.可能编辑觉得太low了., objectType=tool_impact_factor, channel=null, level=null, likeNumber=962, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f0fb2030145, createdName=1e2321c7m65(暂无匿称), createdTime=Wed Dec 27 12:20:00 CST 2017, time=2017-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=547910, encodeId=886354e910ba, content=投了一篇关于biomarker的.没送审.直接被拒了.样本一百多例.采用的是elisa分析目的分子.结合分析临床指标.分析预后等因素.可能编辑觉得太low了., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=916, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/27/dc7b280f49af7fee2e92128f03a39234.jpg, createdBy=d2d11969271, createdName=hongweicheng, createdTime=Wed Oct 04 11:23:00 CST 2017, time=2017-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=533953, encodeId=067153395351, content=审稿速度:1.0 | 投稿命中率:5.0 经验分享：投稿了一篇关于技术改进的回顾性分析，24小时不到就被拒了……（assessed by the Associate Editor and the Board of Editors as the first step in the evaluation of manuscripts ）, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1039, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c881636328, createdName=heeda, createdTime=Fri Mar 10 10:01:00 CST 2017, time=2017-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=531605, encodeId=587c531605b0, content=请问各位前辈：在投稿过程中我一步一步按照顺序填写文章的信息，但作者那栏始终没显示表示该项已填写成功的对号图案，别的栏填完之后都有对号；一路点击next，到了上传files这一步之后再点击next，就到了显示文章现在的状态的页面，始终显示incomplete，不明白为啥啊啊啊啊啊，不明白问题出在了哪儿，求前辈们指导。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=1025, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64c32006937, createdName=Dr.Carrisa, createdTime=Sun Jan 08 15:54:00 CST 2017, time=2017-01-08, status=1, ipAttribution=)]

2017-01-08 Dr.Carrisa

请问各位前辈：在投稿过程中我一步一步按照顺序填写文章的信息，但作者那栏始终没显示表示该项已填写成功的对号图案，别的栏填完之后都有对号；一路点击next，到了上传files这一步之后再点击next，就到了显示文章现在的状态的页面，始终显示incomplete，不明白为啥啊啊啊啊啊，不明白问题出在了哪儿，求前辈们指导。

1025 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务